<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0FA0D9A7-79AE-46F8-85E8-D5DB38EE49E6"><gtr:id>0FA0D9A7-79AE-46F8-85E8-D5DB38EE49E6</gtr:id><gtr:name>Hebrew University of Jerusalem</gtr:name><gtr:address><gtr:line1>Mt Scopus</gtr:line1><gtr:line4>Jerusalem</gtr:line4><gtr:line5>91905</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4392299B-45A0-4B1F-A45B-28B39C51452F"><gtr:id>4392299B-45A0-4B1F-A45B-28B39C51452F</gtr:id><gtr:name>Broad Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Centre for Cardiovascular Science</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0FA0D9A7-79AE-46F8-85E8-D5DB38EE49E6"><gtr:id>0FA0D9A7-79AE-46F8-85E8-D5DB38EE49E6</gtr:id><gtr:name>Hebrew University of Jerusalem</gtr:name><gtr:address><gtr:line1>Mt Scopus</gtr:line1><gtr:line4>Jerusalem</gtr:line4><gtr:line5>91905</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4392299B-45A0-4B1F-A45B-28B39C51452F"><gtr:id>4392299B-45A0-4B1F-A45B-28B39C51452F</gtr:id><gtr:name>Broad Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1CB4512E-B662-46F2-BFFD-915274941D56"><gtr:id>1CB4512E-B662-46F2-BFFD-915274941D56</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Franklin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A272DBEA-0D1F-4203-B758-69698FC352F1"><gtr:id>A272DBEA-0D1F-4203-B758-69698FC352F1</gtr:id><gtr:firstName>Siddharthan</gtr:firstName><gtr:surname>Chandran</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6E21A7D6-BE0F-45B5-9AAD-25FE1CE982B1"><gtr:id>6E21A7D6-BE0F-45B5-9AAD-25FE1CE982B1</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:surname>ffrench-Constant</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0802545"><gtr:id>D32A2426-93A1-489B-B405-31FF0CFF9D67</gtr:id><gtr:title>Development of retinal transplantation as an animal model to test stem cell therapies for myelin diseases</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802545</gtr:grantReference><gtr:abstractText>Stem cells can be used by scientists to form many of the different cell types that make up the human body. They offer exciting new possibilities for treating diseases of the human brain such as multiple sclerosis. By using human stem cells to grow new nerve cells in a dish, and then transplanting them into the brains of patients, we hope to repair the damage caused by the disease. The difficulty is that we have to be completely sure that these cells will not behave in a way that might make the brain damage worse, for example by growing uncontrollably and forming a tumour. Scientists believe that cells that have been completely turned into nerve cells will not cause these problems and will be effective at damage repair, but they do need to prove this each time they want to use a set of cells for treating groups of patients. At the moment this would be done by transplanting the cells into the brains of rats or mice. However, as the brain is a very complicated structure, it is extremely difficult to be completely certain that all the cells are behaving normally. This project proposes a new way of testing cells by placing them in the back of the eye of rats. The nerve fibres at the back of the eye are very similar to those damaged in diseases such as multiple sclerosis. Here, unlike the brain, the transplanted cells can be easily seen and tested. If successful, the project will both reduce the number of animals needed for testing stem cell treatments and also speed up the use of these treatments for brain diseases for which there is presently no cure</gtr:abstractText><gtr:technicalSummary>Cell transplantation represents an important application for stem cell medicine, with potential therapeutic benefit deriving from a combination of cell replacement and stimulation of endogenous repair. Diseases of the central nervous system, with their enormous societal and social costs, represent important targets for such therapies. Of these, the diseases of myelin provide appropriate initial targets; the oligodendrocytes lost or damaged in these diseases represent a functionally homogeneous population which extensive animal studies have established can be replaced by transplanted cells and whose replacement does not require complex targeting strategies. Key problems with transplantation of human ES or iPS cell-derived oligodendrocytes are, however, comparison of efficacy and confirmation of safety. Transplantation into animal models is clearly required, but assessment of behaviour within the complex 3-dimentional environment of the brain is a significant problem and represents a major roadblock in the path to clinical delivery of stem cell medicines. Here, therefore, we will take advantage of the unique architecture of the retina to develop a new preclinical animal model that overcomes these problems. The axons of retinal ganglion cells run in a flat sheet over the surface of the retina prior to their exit into the optic nerve. In the nerve, these axons are fully myelinated but they remain unmyelinated in their retinal portion. This reflects a lack of cells with myelinating capacity rather than any intrinsic properties of the axons, as we and others have shown that transplantation of precursor cells for oligodendrocytes into this retinal nerve fibre layer results in myelination. As the retina can easily be accessed and visualised through the eye in living animals, and then removed and flat mounted for histological analysis that enables quantification of myelination simply by measuring the area of myelinated axons, this has the potential to provide a simple and accurate model of efficacy and safety of myelinogenic cell populations prior to clinical use.</gtr:technicalSummary><gtr:fund><gtr:end>2011-07-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>257358</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Broad Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Braod image analysis</gtr:description><gtr:id>B25D83D0-110D-430E-ADA6-A8CBCCF6D2E4</gtr:id><gtr:impact>none to date</gtr:impact><gtr:partnerContribution>Development of machine learning image analysi protocols</gtr:partnerContribution><gtr:piContribution>Definition of the problem of quantifying myelin sheaths</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>analysis of DISC1 function in neurogenesis</gtr:description><gtr:id>7A8CF53C-D4F0-4E62-8034-2496ED931E94</gtr:id><gtr:impact>No outputs in 2012</gtr:impact><gtr:partnerContribution>Specialist knowledge</gtr:partnerContribution><gtr:piContribution>Post doc in lab working with DISC1 mutant mice</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Hebrew University of Jerusalem</gtr:collaboratingOrganisation><gtr:country>Israel, State of</gtr:country><gtr:description>work on CNS adult neurogenesis</gtr:description><gtr:id>F5A1A61A-07D2-4E94-AE5F-4EB6586E748C</gtr:id><gtr:impact>No outputs in 2012</gtr:impact><gtr:partnerContribution>Work not yet started</gtr:partnerContribution><gtr:piContribution>Work not yet started</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Max Planck Society</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Max Planck Institute for Experimental Medicine</gtr:department><gtr:description>Septin Werner</gtr:description><gtr:id>84301BF1-135F-4B29-B72A-02598A6AC909</gtr:id><gtr:impact>none to date</gtr:impact><gtr:partnerContribution>expert advice and septin antibodies</gtr:partnerContribution><gtr:piContribution>Discovery of myelin abnormalities that might be explained by septin mislocalization</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Yale University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine Yale</gtr:department><gtr:description>yale</gtr:description><gtr:id>1BA995BE-3BE7-4301-A02A-5F4E9D1C1FE0</gtr:id><gtr:impact>Grant from NIH</gtr:impact><gtr:partnerContribution>expertise in vascular biology and stroke models</gtr:partnerContribution><gtr:piContribution>Expertise in stem cell biology and extracellular matrix</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Labroatory for Molecular Cell Biology</gtr:department><gtr:description>ES cell collaboration</gtr:description><gtr:id>E4EAF9B6-F7DD-4663-90FC-64D84A7EE558</gtr:id><gtr:impact>Cell lines established in Edinburgh for testing in the retinal model as outlined in the original application</gtr:impact><gtr:partnerContribution>Expertise in ES cell biology provided to usProvision of cells with mutations causing neurofibromatosis, and expertise in the animal models of the disease</gtr:partnerContribution><gtr:piContribution>Stem cell culture prior to testing in vivo</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Disc1 SC</gtr:description><gtr:id>9E37B11B-3895-4981-A051-558B80572126</gtr:id><gtr:impact>none to date</gtr:impact><gtr:partnerContribution>Human cells and initial results</gtr:partnerContribution><gtr:piContribution>New research tools - fibres</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Stem Cell Research Edinburgh</gtr:department><gtr:description>ES cell collaboration</gtr:description><gtr:id>C364BB24-FFAB-4ABA-8CB5-8112471ABC3E</gtr:id><gtr:impact>Cell lines established in Edinburgh for testing in the retinal model as outlined in the original application</gtr:impact><gtr:partnerContribution>Expertise in ES cell biology provided to usProvision of cells with mutations causing neurofibromatosis, and expertise in the animal models of the disease</gtr:partnerContribution><gtr:piContribution>Stem cell culture prior to testing in vivo</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Edinburgh science festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>10DFC839-0A36-4B16-9752-7AFF39CE1E92</gtr:id><gtr:impact>Questions afterwards

none</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talks to MS Society meetings</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>B102BF8F-C629-446E-9EAD-195806FF09AC</gtr:id><gtr:impact>Platform presentations at MS Meetings for patients

Dissemination of information, and funding donations to Society</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation by Charles ffrench-Constant at MS Society Scotland Perth</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E63773C1-DFBD-4037-B5F6-D403008596BD</gtr:id><gtr:impact>200 patients and staff attended the annual meeting of the Scottish MS Society, where I explained the issues surrounding stem cell transplantation that are addressed by this grant

Further requests to talk to MS groups eg Ayr and Arran and Perth and Kinross, both in 2010</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Charles frrench-Constant lecture at MS Space North annual meeting 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FA1B6DF1-8458-4D14-8226-504DC2A56E05</gtr:id><gtr:impact>MS Space North annual meeting, 16 August 2013, Exhibition Centre, Aberdeen, Scotland. Prof Charles ffrench-Constant was invited to give a keynote lecture. 150 patients with MS and their families attended. Lecture was recorded and is available online (214 views so far): http://www.mssociety.org.uk/ms-events/2013/06/ms-space-north-2013-aberdeen.

Part of a general objective of disseminating information concerning regenerative medicine, generating interest in this field.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.mssociety.org.uk/ms-events/2013/06/ms-space-north-2013-aberdeen</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RSE lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>978C73A5-9B92-4A0A-A786-B0CB2FA77085</gtr:id><gtr:impact>Discussion about MS therapies

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>35000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Edinburgh - MS Society Clinical Science Centre</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:id>BE9B5548-3729-412F-92A6-26394712159C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1900000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Investigator award</gtr:description><gtr:end>2020-02-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>BD5F76B3-6E8F-468D-B187-D182BF3CCE8C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fellowship scheme</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>European Leukodystrophy Association (ELA)</gtr:fundingOrg><gtr:id>08739B57-C905-4C06-9A06-95C49C3BB908</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BIRAX</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>53FCD377-28EC-4CB4-BF3E-FE5DBE3E5036</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Panel discussion at the House of Lords. Tuesday 30 October 2012, London. Charles ffrench-Constant was aksed to give evidence to the Science and Technology Select Committee at the House of Lords. They recently launched their regenerative medicine inquiry and Charles was asked to give oral evidence by being a member of panel (session lasted 55min). In accordance with Lords usual practice, possible questions were provided in advance and the session were be in public and transcribed. The House of Lords Science and Technology Committee, under the Chairmanship of Lord Krebs, is conducting an inquiry into regenerative medicine. The Committee will be looking, in particular, at whether the UK is in a position to facilitate the translation of knowledge from world-leading research to treatments and to benefit from thecommercial opportunities that they present. It also seeks to explore how realistic some of the reported claims of regenerative treatments and therapies are, both in the UK andinternationally.</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>C2766702-1E06-4061-BE17-9D181F274B36</gtr:id><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European Leucodystrophy association committee on imaging in leucodystrpohy. Prof Charles ffrench-Constant has a leading role in this committee meeting, Oct 2013.</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>5508BDC8-D8C3-4470-8DF6-DAA10EC8873C</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CFFC - gave presentation at workshop on Regenerative Medicine at the House of Lords, 23rd Oct, Charles ffrench-Constant</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>71245926-F8C5-4AA8-88D4-11E3FA603ED0</gtr:id><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bristol review</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BD97E9E6-DA08-4215-864C-CBF3BFE1BCF6</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Retinal transplant assay to measure the proliferative potential of myelinating cell populations</gtr:description><gtr:id>1E9EC76A-53FF-49D1-8A2C-58488814320C</gtr:id><gtr:impact>validation of model for the field</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>retinal transplant model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Protocol for differentiating ES cells into oligodendrocytes suitable for myelinating cultures and transplantation</gtr:description><gtr:id>63767CC9-5DC7-4902-839E-D0A1A6DF48F9</gtr:id><gtr:impact>Successful fellowship application to ELA</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ES differentiation into oligodendrocytes</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CF3217F1-05EB-4C72-BDD5-A2E94CD31861"><gtr:id>CF3217F1-05EB-4C72-BDD5-A2E94CD31861</gtr:id><gtr:title>Quiescence and activation of stem and precursor cell populations in the subependymal zone of the mammalian brain are associated with distinct cellular and extracellular matrix signals.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a16f5e538385a01670bdce9acbab2cb1"><gtr:id>a16f5e538385a01670bdce9acbab2cb1</gtr:id><gtr:otherNames>Kazanis I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/99833656-A64B-4FA9-91C0-591042E4AA6E"><gtr:id>99833656-A64B-4FA9-91C0-591042E4AA6E</gtr:id><gtr:title>M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0d39740dc3318268969ee29b33db6d59"><gtr:id>0d39740dc3318268969ee29b33db6d59</gtr:id><gtr:otherNames>Miron VE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3B70AAD7-BF61-412D-A9A0-3C946A03A3D3"><gtr:id>3B70AAD7-BF61-412D-A9A0-3C946A03A3D3</gtr:id><gtr:title>The number of stem cells in the subependymal zone of the adult rodent brain is correlated with the number of ependymal cells and not with the volume of the niche.</gtr:title><gtr:parentPublicationTitle>Stem cells and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a16f5e538385a01670bdce9acbab2cb1"><gtr:id>a16f5e538385a01670bdce9acbab2cb1</gtr:id><gtr:otherNames>Kazanis I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1547-3287</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/73AEFE0B-7168-476C-8BD1-EE173B0E0669"><gtr:id>73AEFE0B-7168-476C-8BD1-EE173B0E0669</gtr:id><gtr:title>Use of induced pluripotent stem-cell technology to understand photoreceptor cytoskeletal dynamics in retinitis pigmentosa</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d9710d3f1bbceff3076101bfa10b46d2"><gtr:id>d9710d3f1bbceff3076101bfa10b46d2</gtr:id><gtr:otherNames>Megaw R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802545</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>